Table 1.
Patient demographics and baseline characteristics
| Barasertib 1,200 mg n = 6 |
|
|---|---|
| Median age (range), years | 63 (34–74) |
| Male/female, n | 3/3 |
| Median body weight (range), kga | 66 (55–85) |
| Race, n | |
| Caucasian | 4 |
| Asian | 2 |
| WHO performance status, n | |
| 0 | 1 |
| 1 | 4 |
| Missing | 1 |
| AML type, n | |
| De novo | 4 |
| Secondary to MDS | 2 |
| AML status, n | |
| Newly diagnosed | 2 |
| First relapse | 1 |
| Second relapse | 3 |
WHO, World Health Organization; MDS, myelodysplastic syndrome
aData missing for one patient that died prior to receiving study treatment